Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer

NCT01141309 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

41

Enrollment

OTHER

Sponsor class

Conditions

Thyroid Cancer

Interventions

DRUG: sorafenib with everolimus

Sponsor

Memorial Sloan Kettering Cancer Center